GSK hands off dermatitis, psoriasis candidate to Dermavant

The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) will shell out £150 million ($200 million) up front to GlaxoSmithKline

Read the full 222 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE